ADVM

Adverum Biotechnologies, Inc.

7.63 USD
+0.03 (+0.39%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Adverum Biotechnologies, Inc. stock is down -19.94% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 37.5% of the previous 8 May’s closed higher than April. 100% of analysts rate it a buy.

About Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc. develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate. The company was incorporated in 2006 and is headquartered in Redwood City, California.

  • Truist Securities
    Wed May 15, 14:20
    buy
    confirm
  • HC Wainwright & Co.
    Fri May 10, 08:31
    buy
    confirm
  • HC Wainwright & Co.
    Tue Apr 30, 06:03
    buy
    initial
  • Mizuho
    Mon Apr 29, 07:32
    buy
    confirm